Living with chronic kidney disease often involves a slow, steady buildup of scar tissue. This process, known as fibrosis, makes it harder for the kidneys to function over time. New research highlights a specific cycle where dying cells release internal components that trigger a state of cellular aging. This creates a loop that keeps the damage going.
Researchers found that this cycle is fueled by a metabolic bridge. Specifically, a pathway involving PFKFB3 helps sustain a harmful environment that promotes scarring. While some treatments like senolytics or specific inhibitors have shown promise in early laboratory tests, they have not yet been proven to reverse existing damage in humans.
Because the disease is complex, the experts suggest that future treatments should move away from single drugs. Instead, they suggest using combinations of therapies timed to the specific stage of the disease. However, these findings are currently based on early research, and many hurdles remain before these strategies can be used in standard clinical practice.
What this means for you:
A cycle of cell death and aging drives kidney scarring, but current treatments can only slow, not reverse, damage.
Common questions
What causes the scarring in chronic kidney disease?
The scarring, or fibrosis, is driven by a self-amplifying loop. When certain cells die, they release mitochondrial DNA. This triggers a pathway that causes cells to enter a state of aging. This process creates a metabolic bridge that sustains and amplifies the damage to the kidney tissue.
Can current treatments reverse the damage to the kidneys?
The research notes that while certain inhibitors can slow the progression of the disease, they cannot block or reverse the scarring that has already occurred. Current findings are based on preclinical studies, meaning they have not yet been proven to reverse damage in human patients.
What are the potential ways to treat this condition in the future?
Future strategies may move toward combination therapies rather than single drugs. These would be tailored to the specific stage of the disease and guided by biomarkers. This approach aims to target the entire network of the disease rather than just one single molecule.
